$Salvage surgery for cervical radioiodine refractory 18F-FDG-PET positive recurrence of papillary thyroid cancer$

Salvage surgery for cervical radioiodine refractory 18F-FDG-PET positive recurrence of papillary thyroid cancer

Purpose: Five percent of patients with differentiated thyroid cancer are diagnosed with radioiodine refractory relapse in the course of the disease. For isolated or oligometastatic cervical recurrence, resection or another local treatment is recommended. In this study, the impact of surgical treatme...

Full description

Bibliographic Details
Main Authors:	C Chiapponi, H Alakus, M Faust, A M Schultheis, J Rosenbrock, M Schmidt
Format:	Article
Language:	English
Published:	Bioscientifica 2021-09-01
Series:	Endocrine Connections
Subjects:	radioiodine refractory disease salvage surgery external beam radiotherapy
Online Access:	https://ec.bioscientifica.com/view/journals/ec/10/9/EC-21-0232.xml

Similar Items

Potential of the drug-regulation iodide uptake in patients for prevention of radioiodine-refractory papillary thyroid cancer
by: Dmitriy Kirillovich Fomin, et al.
Published: (2014-11-01)

<sup>18</sup>F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib
by: Freba Ahmaddy, et al.
Published: (2021-01-01)

Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial
by: M. S. Brose, et al.
Published: (2018-07-01)

Successful pregnancy without disease progression of radioiodine refractory papillary thyroid carcinoma: a case report
by: Yuchen Jin, et al.
Published: (2017-11-01)

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
by: Dario Tumino, et al.
Published: (2017-11-01)

CYTOLOGICAL CHARACTERISTICS OF POSTOPERATIVE METASTASES OF PAPILLARY THYROID CANCER DURING THE DEVELOPMENT OF SECONDARY RADIOIODINE REFRACTORINESS
by: Anna Zelinskaya, et al.
Published: (2020-01-01)

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
by: Chae Moon Hong, et al.
Published: (2017-10-01)

The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer
by: Carla Colombo, et al.
Published: (2020-11-01)

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
by: Lorusso L, et al.
Published: (2016-10-01)

Do Molecular Profiles of Primary Versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ?
by: Cristiane J. Gomes-Lima, et al.
Published: (2021-02-01)

Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation
by: E. V. Borodavina, et al.
Published: (2020-04-01)

Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma
by: Le Ngoc Ha, et al.
Published: (2021-01-01)

Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma
by: Arwa Alsaud, et al.
Published: (2020-03-01)

Low versus high radioiodine activity for ablation of the thyroid remnant after thyroidectomy in Han Chinese with low-risk differentiated thyroid cancer
by: Lv RB, et al.
Published: (2017-08-01)

Tall-cell variant of papillary thyroid carcinoma: literature review and case reports
by: E. V. Borodavina, et al.
Published: (2020-11-01)

Impact of 18F-FDG PET/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC)
by: Elisa Lodi Rizzini, et al.
Published: (2021-08-01)

Salvage Radiation Therapy for Patients With Relapsing Glioblastoma Multiforme and the Role of Slow Fractionation
by: I. Frank Ciernik, et al.
Published: (2020-12-01)

Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis
by: Yu S, et al.
Published: (2019-02-01)

Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer
by: Tremblay G, et al.
Published: (2016-06-01)

Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
by: Thumallapally N, et al.
Published: (2016-08-01)

RADIOIODINE THERAPY OF PAPILLARY THYROID CANCER, COMPLICATED BY A RADIAL MYELITIS. CLINICAL CASE
by: L. M. Farkhutdinova
Published: (2018-06-01)

CRITERIA OF WELL-DIFFERENTIATED THYROID CARCINOMA RESISTANCE TO RADIOIODINE THERAPY
by: P. O. Rumyantsev, et al.
Published: (2015-04-01)

177Lu-DOTATATE and177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
by: Majid Assadi, et al.
Published: (2019-01-01)

Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma – A Real-World Experience
by: Jiang HJ, et al.
Published: (2021-09-01)

Radioiodine-resistant metastases of well-differentiated thyroid cancer, analysis of tumor characteristics and primary surgical intervention
by: M. V. Ostafiychuk, et al.
Published: (2021-10-01)

IEV (Ifosfamide, Epirubicin, VP16) Regimen as Salvage Therapy for Early Relapsed/Refractory non-Hodgkin/Hodgkin Lymphoma
by: Mohammadali Mashhadi, et al.
Published: (2011-09-01)

IEV (Ifosfamide, Epirubicin, VP16) Regimen as Salvage Therapy for Early Relapsed/Refractory non-Hodgkin/Hodgkin Lymphoma
by: Behrooz Najafi, et al.
Published: (2011-10-01)

Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
by: Chiaki Suzuki, et al.
Published: (2021-07-01)

Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
by: Zohreh Maghsoomi, et al.
Published: (2021-05-01)

Evaluation of a Number of Blood Biochemical Markers after Radioiodine Therapy in Papillary Thyroid Cancer Patients
by: Mehrossadat Alavi, et al.
Published: (2017-04-01)

Salvage Reirradiation Options for Locally Recurrent Prostate Cancer: A Systematic Review
by: Jim Zhong, et al.
Published: (2021-09-01)

Recombinant human thyrotropin in radioiodine diagnostics and radioiodine ablation of patients with well-differentiated thyroid cancer: the first experience in Russia
by: Ivan I. Dedov, et al.
Published: (2018-12-01)

Papillary thyroid microcarcinoma
by: V A Smirnova, et al.
Published: (2015-06-01)

Radioiodine-Labeling of Chlorpyrifos and Its Biodistribution in Mice
by: DIAO Yao, et al.
Published: (2015-11-01)

A Novel Reagent for Radioiodine Labeling of New Chemical Entities (NCEs) and Biomolecules
by: Krishan Kumar, et al.
Published: (2021-07-01)

Occurrence of symptomatic meningioma as a second neoplasm in patients with differentiated thyroid cancer treated with radioiodine
by: Nishikant Avinash Damle, et al.
Published: (2012-01-01)

Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient
by: Harry Ross Powers, et al.
Published: (2014-09-01)

Prolonged duration of response in lenvatinib responders with thyroid cancer (Russian translation)
by: A. G. Gianoukakis, et al.
Published: (2018-11-01)

Comparison of three methods used for measurement of radioiodine fixation in thyroid gland of mice
by: Jeremić Marija Ž., et al.
Published: (2013-01-01)

Restaging of differentiated thyroid carcinoma with SPECT/CT after radioiodine therapy
by: Mariya Alekseevna Karalkina, et al.
Published: (2015-07-01)